SEC Form 4Coverage since Jun 30, 2026
$NVCT insider trading
Over the last 12 months, Nuvectis Pharma insiders reported 2 buys totaling $1.2M and no sales across SEC Form 4 filings.
- Bought · 12m
- $1.2M 2 events
- Sold · 12m
- — 0 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $NVCT · 12Mvia TradingView
Top insiders · 12m
Mosseri Marlio Charles—1× · $916K
BENTSUR RONChairman & CEO1× · $250K
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Mosseri Marlio Charles10% | ▲ Buy | 50,000 | $18.32 | $916K | +1.6% | indirect |
| Jun 30, 2026 | BENTSUR RONChairman & CEO · O·D·10% | ▲ Buy | 12,500 | $20 | $250K | +0.3% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NVCT feed.